Chronic Lymphocytic Leukemia

During a Targeted Oncology™ Case-Based Roundtable™ event, Andrew Lipsky, MD, discussed recent data related to treatment of chronic lymphocytic leukemia, including the ALPINE trial of zanubrutinib.

A recent study found that CXC chemokine ligand 13 and galectin-9 could be prognostic biomarkers of progression-free survival and treatment response in patients with chronic lymphocytic leukemia.

The application for lisocabtagene maraleucel in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma has been accepted by the FDA, following positive results from the TRANSCEND CLL 004 study.

In the second article of a 2-part series, William G. Wierda, MD, PhD, looks at the efficacy and safety outcomes with the second generation BTK inhibitor zanubrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.

In an interview with Targeted Oncology, Skye Montoya discussed noncovalent Bruton's tyrosine kinase inhibitors and mechanisms of resistance in chronic lymphocytic leukemia.

In the first article of a 2-part series, William G. Wierda, MD, PhD, discusses the role Bruton tyrosine kinase inhibitors play in the relapsed/refractory chronic lymphocytic leukemia setting.

Progression-free survival and overall survival data were maintained with fixed-duration venetoclax plus rituximab among patients with relapsed/refractory chronic lymphocytic leukemia

Findings of the phase 1b/2 EPCORE CLL-1 trial were presented during the International Workshop on CLL.

Findings from the phase 1/2 BRUIN trial of show a distinct genetic evolution in patients with B-cell malignancies. However, the baseline BTK mutations did not impede pirtobrutinib’s effectiveness.

Justin Taylor, MD, discusses the treatment landscape for chronic lymphocytic leukemia and background on his early research assessing NX-2127 for this patient population.

In the phase 3 GLOW study, ibrutinib plus venetoclax significantly improved progression-free survival and other outcomes in patients with chronic lymphocytic leukemia, across most genomic subgroups.

Results from the BRUIN study focusing on patients with chronic lymphocytic leukemia/small lymphocytic lymphoma showed benefit in patients were pretreated with Bruton tyrosine kinase inhibitors.

Venetoclax has given new hope and better options to a notoriously hard-to-treat patient group.

Modern fixed-duration therapy has been based on the results shown by 2 approaches: the combination of venetoclax and an anti-CD20 monoclonal antibody and the dual combination of venetoclax and ibrutinib.

Combination therapies utilizing ofatumumab could improve outcomes for patients with chronic lymphocytic leukemia, according to an analysis published in the Annals of Hematology.

Lisaftoclax is a novel, orally administered small-molecule BCL-2 selective inhibitor. A study of the agent in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma will commence in the second half of 2023.

In an interview with Targeted Oncology, Cyrus M. Khan, MD reviewed the recent FDA approvals is the chronic lymphocytic leukemia space. He also discusses other FDA decisions that have recently altered the landscape for the better.